Ultimovacs (OB:ULTI) - Hisse Senedi Fiyatı, Haberler ve Analizler

ULTI Stoklara Genel Bakış

Bir biyoteknoloji şirketi olan Ultimovacs ASA, Norveç'te kanserlere karşı immünoterapiler geliştirmektedir. Daha fazla detay

ULTI temel anali̇z
Kar Tanesi Skoru
Değerleme	2/6
Gelecekteki Büyüme	2/6
Geçmiş Performans	0/6
Finansal Sağlık	5/6
Temettüler	0/6

Ödüller

Gelirin yılda 39.45% oranında artması öngörülüyor

Risk Analizi

Anlamlı bir piyasa değeri yok ( NOK70M )

Geliri 1 milyon ABD dolarından az ( NOK0 )

Son 3 ayda hisse senedi fiyatı oldukça dalgalıydı

1 yıldan az nakit akışı var

+ 1 daha fazla risk

Ultimovacs ASA Rakipler

Arctic Bioscience

OB:ABS

NOK 49.5m

PCI Biotech Holding

OB:PCIB

NOK 54.3m

EXACT Therapeutics

OB:EXTX

NOK 192.5m

Nordic Nanovector

OB:NANOV

NOK 231.8m

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti Ultimovacs
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	NOK 2.03
52 Haftanın En Yüksek Seviyesi	NOK 165.00
52 Haftanın En Düşük Seviyesi	NOK 1.57
Beta	0.99
11 Aylık Değişim	12.90%
3 Aylık Değişim	-25.91%
1 Yıllık Değişim	-98.12%
33 Yıllık Değişim	-98.12%
5 Yıllık Değişim	-93.51%
Halka arzdan bu yana değişim	-93.45%

Son Haberler & Güncellemeler

Recent updates

Here's Why We're Not At All Concerned With Ultimovacs' (OB:ULTI) Cash Burn Situation

Jul 27

We're Hopeful That Ultimovacs (OB:ULTI) Will Use Its Cash Wisely

Mar 23

Have Insiders Sold Ultimovacs ASA (OB:ULTI) Shares Recently?

Feb 13

Hissedar Getirileri

	ULTI	NO Biotechs	NO Pazar
7D	-10.6%	8.6%	-0.9%
1Y	-98.1%	-61.7%	2.5%

Getiri vs. Endüstri: ULTI geçen yıl % -62.9 oranında getiri sağlayan Norwegian Biotechs sektörünün gerisinde kaldı.

Getiri vs Piyasa: ULTI geçen yıl % 3.6 oranında getiri sağlayan Norwegian Piyasasının altında performans gösterdi.

Fiyat Oynaklığı

Is ULTI's price volatile compared to industry and market?
ULTI volatility
ULTI Average Weekly Movement	14.8%
Biotechs Industry Average Movement	11.8%
Market Average Movement	5.1%
10% most volatile stocks in NO Market	10.5%
10% least volatile stocks in NO Market	2.7%

İstikrarlı Hisse Senedi Fiyatı: ULTI hisse senedi fiyatı son 3 aydır dalgalı bir seyir izliyor.

Zaman İçindeki Volatilite: ULTI 'nin haftalık oynaklığı son bir yılda 20% dan 15% a düştü, ancak hâlâ Norwegian hisselerinin %75'inden yüksek.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
2011	17	Carlos de Sousa	www.ultimovacs.com

Bir biyoteknoloji şirketi olan Ultimovacs ASA, Norveç'te kanserlere karşı immünoterapiler geliştirmektedir. Lider ürün adayı, pan-tümör antijeni telomeraza karşı spesifik bir T hücresi yanıtını indükleyen peptit bazlı bir terapötik kanser aşısı olan UV1'dir. Ultimovacs ASA 2011 yılında kurulmuştur ve merkezi Oslo, Norveç'tedir.

Ultimovacs ASA Temel Bilgiler Özeti

Ultimovacs'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
ULTI temel i̇stati̇sti̇kler
Piyasa değeri	NOK 69.84m
Kazançlar(TTM)	-NOK 149.28m
Gelir(TTM)	n/a

0.0x

P/S Oranı

-0.5x

F/K Oranı

ULTI aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
ULTI gelir tablosu (TTM)
Gelir	NOK 0
Gelir Maliyeti	NOK 0
Brüt Kâr	NOK 0
Diğer Giderler	NOK 149.28m
Kazançlar	-NOK 149.28m

Son Raporlanan Kazançlar

Sep 30, 2024

Sonraki Kazanç Tarihi

Feb 13, 2025

Hisse başına kazanç (EPS)	-4.34
Brüt Marj	0.00%
Net Kâr Marjı	0.00%
Borç/Özkaynak Oranı	0%

ULTI uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

ULTI Stoklara Genel Bakış

Ödüller

Risk Analizi

Ultimovacs ASA Rakipler

OB:ABS

NOK 49.5m

OB:PCIB

NOK 54.3m

OB:EXTX

NOK 192.5m

OB:NANOV

NOK 231.8m

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

Ultimovacs ASA Announces Publication of Phase II FOCUS Trial Results on MedRxiv

New major risk - Market cap size

Ultimovacs ASA Announces Resignation of Ketil Fjerdingen as Deputy Board Member

Ultimovacs ASA Announces Topline Data from FOCUS Phase II Trial of UV1 Combined with Pembrolizumab in Patients with Metastatic or Recurrent Head and Neck Cancer

Ultimovacs Asa Announces Poster Presentation of Nipu Phase II Trial Update At Upcoming ESMO Congress 2024

Ultimovacs Asa Provides Update from Phase I Study in Malignant Melanoma

Recent updates

Ultimovacs ASA Announces Publication of Phase II FOCUS Trial Results on MedRxiv

New major risk - Market cap size

Ultimovacs ASA Announces Resignation of Ketil Fjerdingen as Deputy Board Member

Ultimovacs ASA Announces Topline Data from FOCUS Phase II Trial of UV1 Combined with Pembrolizumab in Patients with Metastatic or Recurrent Head and Neck Cancer

Ultimovacs Asa Announces Poster Presentation of Nipu Phase II Trial Update At Upcoming ESMO Congress 2024

Ultimovacs Asa Provides Update from Phase I Study in Malignant Melanoma

No longer forecast to breakeven

New major risk - Revenue and earnings growth

Ultimovacs ASA Implements Operational Adjustments to Support Continuous Advancement of the UV1 Vaccine Phase II Program

Price target decreased by 8.6% to kr155

New minor risk - Market cap size

Ultimovacs Announces Topline Results from INITIUM Study Evaluating UV1 Vaccination Added to Ipilimumab and Nivolumab in Patients with Unresectable or Metastatic Malignant Melanoma

New minor risk - Share price stability

Companies Like Ultimovacs (OB:ULTI) Can Afford To Invest In Growth

Ultimovacs Receives FDA Fast Track Designation for UV1 Cancer Vaccine for the Treatment of Patients with Unresectable Mesothelioma

Ultimovacs ASA Updates Timeline for Reporting on Randomized UV1 Phase II Trial Initium in Malignant Melanoma

Ultimovacs ASA to Report Q4, 2024 Results on Feb 13, 2025

Insufficient new directors

Ultimovacs ASA Announces Resignation of Aitana Peire from Board of Directors

Ultimovacs ASA Announces Resignation of Aitana Peire from Board of Directors

Chief Executive Officer recently bought kr57k worth of stock

No longer forecast to breakeven

Ultimovacs ASA Announces Completion of Patient Enrollment in Supplementary Study to INITium, UV1 Phase II Trial in Malignant Melanoma

Ultimovacs ASA Announces Protocol Amendment in UV1 Phase II Study INITIUM in Malignant Melanoma, Enabling Data Readout in First Half of 2024

Ultimovacs (OB:ULTI) Is In A Strong Position To Grow Its Business

Ultimovacs ASA Announces Full Dataset from the NIPU Clinical Trial (Nct04300244) Presented At the ESMO Congress 2023 in Madrid

Ultimovacs ASA Announces the Results from the NIPU clinical trial (NCT04300244)

New minor risk - Share price stability

Ultimovacs Provides 4-Year Update from Phase I Study in Malignant Melanoma: Demonstrating Sustained Long-Term Overall Survival in Patients Treated with Uv1 Cancer Vaccine

Ultimovacs ASA Receives FDA Orphan Drug Designation for the Uv1 Cancer Vaccine for Treatment of Mesothelioma

Ultimovacs ASA Announces the Results from Uv1 Phase Ii Clinical Trial Nipu in Malignant Mesothelioma Will Be Presented At the Esmo Congress 2023

Ultimovacs Announces Completed Enrollment in FOCUS Phase II Clinical Trial of UV1 in Head and Neck Cancer Patients

Ultimovacs ASA Announces Publication in Clinical Cancer Research of the UV1-103 Phase I Malignant Melanoma Trial Results

Ultimovacs Provides 3-Year Update from Phase I Study in Malignant Melanoma: Results Confirm Strong Overall Survival in Patients Treated with UV1 Cancer Vaccine

New minor risk - Share price stability

Ultimovacs ASA Provides Update on Phase II NIPU Trial Evaluating UV1 in Second-Line Patients with Malignant Leural Mesothelioma

No longer forecast to breakeven

Ultimovacs ASA Announces Completion of Patient Recruitment in NIPU Phase II Clinical Trial of UV1 in Mesothelioma

Ultimovacs ASA, Annual General Meeting, Apr 18, 2024

Ultimovacs ASA Announces Cemiplimab to Replace Pembrolizumab in V1 Phase II LUNGVAC Trial

Ultimovacs ASA Completes Last Patient Enrollment in Phase I TENDU Trial in Prostate Cancer

Chief Executive Officer recently bought kr145k worth of stock

Forecast to breakeven in 2023

No independent directors

No longer forecast to breakeven

Ultimovacs Announces First Patient Randomized in Phase II LUNGVAC Trial of UV1 in Non-Small Cell Lung Cancer (NSCLC)

Ultimovacs Asa Announces New Uv1 Data Showing Enhanced Efficacy Including in Hard-To-Treat Cancer Patients, Supporting Broad Utility

Ultimovacs Asa Announces New Uv1 Data Showing Enhanced Efficacy Including in Hard-To-Treat Cancer Patients, Supporting Broad Utility

Ultimovacs ASA Announces Positive Three-Year Results of 71% Overall Survival Rate in Cohort 1 of UV1-103 Study in Metastatic Malignant Melanoma

Companies Like Ultimovacs (OB:ULTI) Are In A Position To Invest In Growth

Ultimovacs ASA Announces Publication of Phase I Melanoma Trial Data in Journal of Translational Medicine

Chief Executive Officer recently bought kr134k worth of stock

Price target increased to kr151

Ultimovacs ASA Expands High Dose Cohort Size in Tendu Phase I Prostate Cancer Trial After Safety Review

Ultimovacs Completes Patient Recruitment in INITIUM Phase II Trial of UV1 in Malignant Melanoma

Ultimovacs ASA Announces UV1 Cancer Vaccine Shows Strong Overall Survival in Malignant Melanoma Phase I Trial

Ultimovacs (OB:ULTI) Is In A Good Position To Deliver On Growth Plans

Ultimovacs Announces Presentation of UV1 Immune Monitoring Data At Cancer Immunotherapy Annual Meeting

Price target increased to kr151